INTRODUCTION

R
aman spectroscopy can provide details of the chemical composition of tissues. It is a nondestructive technique requiring no sample preparation, making it an attractive method for in vivo and in vitro characterization of biological tissues. A Raman spectrum
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ABSTRACT:
Raman spectroscopy shows potential in differentiating tumors from normal tissue. We used Raman spectroscopy provides a molecular fingerprint, and the intensity of the Raman peaks is directly proportional to the concentration of the molecules. Traditional disease classification including cancer is based on the morphologic appearance of tissues (histology). These morphologic changes are accompanied by changes in chemical composition. Thus, Raman spectroscopy is likely to be a useful technique. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] The objectives of this study were to evaluate the sensitivity and specificity of Raman spectroscopy in differentiating between cancer and normal breast tissue in a mouse model.
MATERIALS AND METHODS
Animal Experiments
All experiments received prior approval from the Animal Investigation Committee at Wayne State University. A highly malignant BALB/c tumor cell line (4T1) was used in this study. 12 Eleven BALB/c (Taconic Farms, Germantown, NY) female mice (6-to 8-weeks old) were injected subcutaneously at the nipple of the 5th mammary gland on one side, with a suspension of 1 3 10 5 4T1 tumor cells. All mice developed tumor nodules at the injection site. The mice were humanely killed 10-14 days following injection. Tumors and adjacent breast tissue were removed for analysis. Adjacent breast tissue often included lymph nodes. The contralateral mammary gland and its adjacent lymph nodes were also removed. Specimens were evaluated histologically and with near-infrared (NIR) Raman spectroscopy. When lymph nodes were found histologically, they were also analyzed with Raman spectroscopy. Samples were divided in two. One was submitted for histology and one for Raman spectroscopy. After Raman spectroscopy, the samples used for Raman analysis were also submitted for histology.
Histology
Samples were fixed in 10% (v/v) neutral buffered zinc formalin solution (Richard Allan Scientific) and processed overnight. Following embedding, 5 lm sections were cut and stained with hematoxylineosin.
NIR Raman Spectroscopic Measurements
Raman spectra were recorded using a Renishaw Raman microscope (RM1000, equipped with a thermoelectric cooled 578 3 385 pixel CCD), using a 203 objective in the 600-1800 cm 21 spectral range. A 785 nm laser line was used to excite the Raman spectra with 50 mW of power at the sample. The spectra were collected in linemode with a measured length and width of laser excitation of 130 lm 3 25 lm. Typical cell size is on the order of 20 lm, and the line-mode was used to acquire spectra from a range of cells. This should be the preferred method in the operating room, as the surgeon would be unable to sample each cell individually because of limited cell selectivity and time constraints.
All Raman measurements used a 10 s exposure time, and three exposures were averaged to obtain a better signal-to-noise ratio. The spectral resolution was 4 cm 21 . To assess intrasample variability, multiple measurements (n ! 12) were made on each sample at different regions. This was accomplished by placing samples on an xyz motorized, computer-controlled sample stage. Points to be analyzed were chosen randomly from the microscopic image of the tissue available on the Renishaw spectrometer.
Raman Spectrum Processing
Raman spectra of tissues contain a combination of Raman scattering, intrinsic tissue fluorescence, and noise. Preprocessing steps include cosmic-ray removal, noise subtraction, and removal of tissue fluorescence and normalization of the data. Each spectrum was represented as a set of 601 variables at 2 cm 21 intervals. A median filter was applied to the raw data to eliminate cosmic rays or spikes. Then noise was filtered using wavelets. 13 The background fluorescence was subtracted from the denoised spectra using a modified cubic spline algorithm. Unlike other cubic spline fits, this algorithm requires no a priori knowledge of the spectra.
14 The subtracted spectrum was normalized so that the minimum and maximum values of the spectrum were 0 and 1, respectively. Matlab version 6.5 was used to preprocess the data.
Tissue Classification Methods and Data Analysis
Principal component (PC) analysis was first used to reduce the dimensionality of the dataset to simplify the data analysis. Discriminant function analysis (DFA) was used for tissue classification. It is a supervised classification method that builds classification rules for a number of prespecified categories. 15 It correlates the weighting coefficients (scores) of the PCs calculated for each Raman spectrum with diagnostic categories. A leave-one-out classification algorithm was used to ensure the validity of the analysis.
RESULTS
Histological Evaluations
From the contralateral side, we collected normal breast tissue which often contained lymph nodes (Figure 1a) . From the injected side, we collected tumor (Figure 1b) , and adjacent breast tissue with lymph nodes (Figure 1c ). We will refer to adjacent breast tissue with its accompanying lymph nodes as the tumor bed. Histology confirmed poorly differentiated adenocarcinoma in all 17 tumor samples. No definite tumor cells were found in any of the normal mammary tissue (tumor bed or contralateral), and no definite tumor cells were found in any of the lymph nodes from either side. The tumor bed samples showed reactive stromal cells, some inflammatory cells, and a few scattered large atypical cells with large hyperchromatic nuclei and a moderate amount of cytoplasm; however, they displayed no definite tumor aggregates (Figure 1c ). In practice, atypical cells are hard to classify and are often overlooked. Two mice showed mastitis (fat necrosis and chronic inflammation) in their mammary gland tissue, one from tumor bed and two from contralateral breast (Figure 1d ).
Raman Spectroscopy
We collected 650 spectra. Because of the small size of the mammary glands and lymph nodes, we were not able to separate these tissues grossly. Some of the breast tissue samples contained tiny lymph nodes, and some of the lymph node samples contained breast tissue. For this reason, we analyzed the spectra in four diagnostic categories: (a) contralateral breast with lymph node, (b) tumor, (c) tumor bed, and (d) mastitis. Figure 2 shows the corresponding normalized mean Raman spectra. Note the visual differences in the peak heights of the four spectra.
Data Analysis
Mean Spectra Analysis. We first conducted an analysis of normal, tumor, and mastitis tissues to confirm the diagnostic ability of DFA. Raman and histology agreed in all cases, except one tumor sample which was more characteristic of normal tissue (Table I ). This may be because the sample was largely made up of normal cells, with fewer tumor components.
We then analyzed the data using all four tissues-that is including tumor bed (Figure 2 ). These were also analyzed using DFA, with PC scores as the input using leave-one-out analysis. We used the mean spectra of each tissue to analyze the data, and then reanalyzed the data using individual spectra (Table II) .
Using mean spectra, 14 of 17 normal samples were correctly identified, 16 of 17 tumor samples were correctly identified, and all mastitis samples were correctly identified. Raman accuracy decreased slightly when including tumor bed, presumably because some tumor bed samples had characteristics of tumor while some had characteristics of normal tissue. Of 18 tumor bed samples, 9 were similar to the contralateral breast (normal), and 6 had specific changes separating them from normal tissue, 2 showed changes consistent with mastitis, and only 1 sample showed changes consistent with the other tumor samples. All mastitis samples were correctly identified.
Individual Spectra Analysis. Individual spectra also confirmed the ability of Raman to differentiate normal, tumor, and mastitis tissues. All normal and mastitis spectra were correctly identified, and 91% of tumor spectra were correctly identified. The other 9% were classified as normal and mastitis, consistent with normal pockets trapped within the tumor.
Using individual spectra, 79% of normal tissue samples were correctly identified, while the other 21% were identified as tumor bed. Within the tumor group, 0.4% were identified as normal, 10% were called tumor bed, 2.2% were called mastitis, and 87.3% were called tumor. All mastitis samples were correctly identified. Within the tumor bed, 49.2% of samples were identified as normal, 5.6% were identified as The number in each column represents the number of cases per group as classified by the diagnostic method. Normal  17  14  3  189  150  39  Tumor  17  16  1  229  1  200  5  23  Mastitis  3  3  37  37  Tumor bed  18  9  1  2  6  195  96  11  10  78 The number in each column represents the number of cases per group as classified by the diagnostic method.
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tumor, 5.1% were identified as mastitis, and 40% were accurately called tumor bed.
DISCUSSION
Several literature sources identify specific molecular structures with specific Raman peaks. The relevant peak assignments for our data are noted in Table III The spectral profile of tumor bed (Figure 2c ) produced the same peaks as normal mammary gland tissue, with some slight changes in the peak intensities. 
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Mastitis is characterized by destruction of mature adipose tissue with sheets of inflammatory cells and foamy macrophages. Raman spectra of mastitis (Figure 2d ) lacked the phospholipid peak at 1747 cm 21 and showed superimposed peaks in the 1200-1500 cm 21 region, resulting in a noticeably broad spectral feature.
Other studies have also shown the ability of Raman spectroscopy to accurately classify diseased tissue in brain, 16, 17 skin, [18] [19] [20] [21] [22] [23] [24] cervix, [25] [26] [27] breast, 1,2,9,10,28-33 and other organs. 8, 11, [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] Our data is confirmatory, and, in addition, demonstrates changes in the tumor bed, which probably represent the detection of chemical signs of preneoplastic changes. Not every Raman spectra correctly classifies every tissue sample. The reason that some spectra from a sample are different is that all samples contain a variety of tissues, such as blood vessels, residual normal organ tissue, and fat. 25, 26 For example, Figure 3 shows the Raman spectra of six different points on the same tumor sample. There are clear differences in the spectral (and therefore chemical) compositions between points b, c, d, e, and a and f, which may reflect two trapped normal components within a tumor sample. Even tumor samples can be expected to contain normal blood vessels and fat. Thus, it would not be a rare event for the Raman microscope to interrogate normal tissue within the tumor. For this reason we take at least 12 spectra from each sample and eliminate the obviously aberrant spectra. We then decide on the diagnosis using the average of all spectra obtained from that sample. Our results firmly support the ability of Raman spectra, when appropriately averaged, preprocessed, and analyzed, to reach the same diagnostic conclusions as histology. While these results are promising, they may misconstrue the actual diagnostic ability of Raman spectroscopy. All spectra were collected under controlled conditions with little intersample variability, under the supervision of trained pathologists. In a less-controlled in vivo study, the diagnostic ability may be reduced because of increased variability in collection method and less premeasurement knowledge of the sample.
In clinical practice, malignant tumors are usually excised with a significant amount of surrounding normal tissue to guarantee complete removal of atypical and preneoplastic cells. Raman spectroscopy indicates that surrounding normal tissue is not the same as the contralateral normal breast. Most of the ''errors'' that were made were in classification of the tumor bed. Some tumor bed tissues were distinctly different from normal, tumor, and mastitis tissues. This may reflect malignant molecular alterations prior to morphologic changes, as would be expected in preneoplastic processes.
Before Raman can be translated to in vivo use, many barriers must be overcome. A new system should be designed, which can be integrated into an existing surgical tool, such as an endoscope or needle biopsy system. To meet this challenge, a fiber-optic probe must be designed, which can be inserted into the needle or endoscope. Ideally, the fiber would reduce the collection time to fractions of a second while also reducing fluorescence. Accompanying software must preprocess and classify the data in near real-time to give an immediate diagnosis in the operating room.
Our study demonstrates that tissues have characteristic Raman spectral features that differentiate pathologic changes like mastitis and cancer from normal breast tissue in a mouse model. It also suggests that Raman spectroscopy can detect molecular preneoplastic changes prior to histologic alterations. This is a rapid technique and requires no prior preparation of tissue. Tissue can be examined in vitro or in vivo in seconds, and if a library of spectral profiles of various tissues and pathologic conditions is created, comparison and interpretation can be performed in real-time. It may offer a quicker, less-subjective method to detect cancer as a supplement to current histological methods. With the rapid development and improvement of optic and computer technology, fiber-optic Raman probes may be used by clinicians to detect malignancy and by surgeons to guide surgical excisions in the not very distant future.
